{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:49:17Z","timestamp":1696967357858},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.2515\/therapie:2005022","type":"journal-article","created":{"date-parts":[[2007,3,12]],"date-time":"2007-03-12T04:04:34Z","timestamp":1173672274000},"page":"175-181","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation de la tol\u00e9rance r\u00e9nale du t\u00e9nofovir dans une cohorte de 107 patients"],"prefix":"10.1016","volume":"60","author":[{"given":"Pierre","family":"Lochet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hel\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Le Moing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Blayac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2005022_bb1415","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2165\/00003495-200363150-00006","article-title":"Tenofovir disoproxil fumarate","volume":"63","author":"Chapman","year":"2003","journal-title":"Drugs"},{"key":"10.2515\/therapie:2005022_bb1420","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1386-6532(01)00167-6","article-title":"Antiviral drugs: current state of the art","volume":"22","author":"De Clercq","year":"2001","journal-title":"J Clin Virol"},{"key":"10.2515\/therapie:2005022_bb1425","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1592\/phco.23.1.29.31915","article-title":"Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection","volume":"23","author":"Antoniou","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie:2005022_bb1430","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1081\/NCN-100002341","article-title":"Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs","volume":"20","author":"Cihlar","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.2515\/therapie:2005022_bb1435","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00126334-200403010-00007","article-title":"Renal tubular dysfunction associated with tenofovir therapy","volume":"35","author":"Peyriere","year":"2004","journal-title":"J Acqur Immune Defic Syndr"},{"key":"10.2515\/therapie:2005022_bb1440","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00002030-200404300-00019","article-title":"Renal safety of tenofovir in HIV treatment-experienced patients","volume":"18","author":"Izzedine","year":"2004","journal-title":"AIDS"},{"key":"10.2515\/therapie:2005022_bb1445","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00002030-200401230-00035","article-title":"Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution","volume":"18","author":"Gaspar","year":"2004","journal-title":"AIDS"},{"key":"10.2515\/therapie:2005022_bb1450","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie:2005022_bb1455","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1053\/ajkd.2002.36924","article-title":"Fanconi syndrome and renal failure induced by tenofovir: a first case report","volume":"40","author":"Verhelst","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.2515\/therapie:2005022_bb1460","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00002030-200304110-00026","article-title":"Renal lesions in HIV-1 positive patient treated with tenofovir","volume":"17","author":"Creput","year":"2003","journal-title":"AIDS"},{"key":"10.2515\/therapie:2005022_bb1465","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00000441-200212000-00011","article-title":"Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity","volume":"324","author":"Coca","year":"2002","journal-title":"Am J Med Sci"},{"key":"10.2515\/therapie:2005022_bb1470","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/376643","article-title":"Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome","volume":"37","author":"Schaaf","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie:2005022_bb1475","series-title":"Echelle ANRS de cotation de la gravit\u00e9 des \u00e9v\u00e9nements ind\u00e9sirables chez l\u2019adulte. Version n\u00b04","author":"Anonyme","year":"2000"},{"key":"10.2515\/therapie:2005022_bb1480","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.2515\/therapie:2005022_bb1485","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1097\/00002030-200206140-00008","article-title":"Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study","volume":"16","author":"Schooley","year":"2002","journal-title":"AIDS"},{"key":"10.2515\/therapie:2005022_bb1490","first-page":"448A","article-title":"Prevalence of electrolyte and acid base disorders in HIV patients [abstract SA-PO890]","volume":"13","author":"Isnard-Bagnis","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.2515\/therapie:2005022_bb1495","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7326\/0003-4819-139-5_Part_1-200309020-00006","article-title":"Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial","volume":"139","author":"Squires","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie:2005022_bb1500","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2165\/00003088-200443090-00003","article-title":"Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics","volume":"43","author":"Kearney","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie:2005022_bb1505","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMe020098","article-title":"NPT2a: the key to phosphate homeostasis","volume":"347","author":"Kronenberg","year":"2002","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2005022_bb1510","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1086\/320893","article-title":"Renal diseases associated with human immunodeficiency virus infection: epidemiology, clinical course and management","volume":"33","author":"Szczech","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.2515\/therapie:2005022_bb1515","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00126334-200302010-00013","article-title":"Development of proteinuria or elevated serum creatinine and mortality in HIV infected women","volume":"32","author":"Gardner","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.2515\/therapie:2005022_bb1520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/00002030-199301000-00024","article-title":"Dideoxyinosine-associated nephrotoxicity","volume":"7","author":"Crowther","year":"1993","journal-title":"AIDS"},{"key":"10.2515\/therapie:2005022_bb1525","article-title":"Rare occurrence of renal toxicity when retrospectively evaluating the use of tenofovir DF in 2 clinical practices [abstract TuPeB4632]","author":"Scott","year":"2004"},{"key":"10.2515\/therapie:2005022_bb1530","article-title":"Incidence of tenofovir-related nephrotoxicity in a large outpatient cohort [abstract WePeB5937]","author":"Jaegel-Guedes","year":"2004"},{"key":"10.2515\/therapie:2005022_bb1535","article-title":"Tenofovir is associated with mild renal dysfunction [abstract WePeB5941]","author":"Mauss","year":"2004"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716302827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716302827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T02:54:52Z","timestamp":1554260092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716302827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0040595716302827"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2005022","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}